2. UroToday Home
  3. Conference Highlights
  4. 11th International Symposium on Targeted Alpha Therapy, TAT-11

TAT-11: High-Purity Actinium-225 Production from Radium-226 Using a Superconducting Electron Linac

Ottawa, ON, Canada (UroToday.com) Dr. Grimm described a commercial production of Ac225 by Niowave, Inc. They use an electron linac where the electron beam hits a target to produce a photon beam, which then bombards a Ra(NO3)2 target. The process precedes as Ra226(gamma, n)Ra225 followed by Ra225 beta decay to Ac225. This produces very pure Ac225 with no Ac227 contamination.

The Ac225 is extracted using commercial resins for separation. They are capable of producing 1 mCi batches now and expect to scale up to 100 mCi/week by 2025. The company has obtained an NRC license to irradiate the Ra target and extract Ac225. They are currently seeking partners for producing Abasedaseed pharmaceutical compounds.


Presented by: Terry Grimm, MD, Niowave, Inc., Lansing, Michigan, United States

Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10)  April 1 - April 4, 2019 - Ottawa, ON, Canada